Literature DB >> 24225743

Comparison of outcomes of group O vs non-group O premature neonates receiving group O RBC transfusions.

Leonard I Boral1, Zane G Staubach, Reny de Leeuw, Duncan C Macivor, Richard Kryscio, Henrietta S Bada.   

Abstract

OBJECTIVES: At some institutions all infants requiring RBC transfusions in neonatal intensive care units (NICUs) receive only group O RBCs. Although transfused group O plasma is minimized in packed RBCs, small amounts of residual anti-A, anti-B, and anti-A,B in group O packed RBCs may bind to the corresponding A and B antigens of non-group O RBCs, possibly hemolyzing their native RBCs and thereby releasing free hemoglobin, theoretically resulting in hypercoagulability and promoting bacterial growth from free iron.
METHODS: Premature infants in the University of Kentucky Children's Hospital NICU database who were transfused (all received group O transfusions) were compared for a number of severity markers to determine if non-group O patients had worse outcomes than group O patients.
RESULTS: In this NICU sample, 724 neonates received at least 1 blood component. No significant differences were found between group O and non-group O infants with regard to final disposition or complications.
CONCLUSIONS: This reassuring finding validates the longstanding neonatal transfusion practice of using group O packed RBCs for infants of all blood groups in the NICU. However, a recent study shows increased mortality from necrotizing enterocolitis in group AB neonates at a facility transfusing only group O RBCs to neonates of all blood groups and suggests a change in neonatal transfusion practice to ABO group-specific RBCs; therefore more studies may be warranted.

Entities:  

Keywords:  Group O transfusion; NICU; Non-group O; RBC transfusions

Mesh:

Substances:

Year:  2013        PMID: 24225743      PMCID: PMC4349557          DOI: 10.1309/AJCPJX94SPZLQLGG

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

Review 1.  Guidelines for assessing appropriateness of pediatric transfusion.

Authors:  Susan D Roseff; Naomi L C Luban; Catherine S Manno
Journal:  Transfusion       Date:  2002-11       Impact factor: 3.157

2.  Feasibility and safety of AS-3 red blood cells for neonatal transfusions.

Authors:  R G Strauss; L F Burmeister; K Johnson; G Cress; D Cordle
Journal:  J Pediatr       Date:  2000-02       Impact factor: 4.406

3.  Decreased survival in necrotizing enterocolitis is significantly associated with neonatal and maternal blood group: the AB isoagglutinin hypothesis.

Authors:  T Thomson; O Habeeb; P J Dechristopher; L Glynn; S Yong; J Muraskas
Journal:  J Perinatol       Date:  2011-11-17       Impact factor: 2.521

4.  How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products.

Authors:  Magali J Fontaine; Anne M Mills; Susan Weiss; Wan-Jen Hong; Maurene Viele; Lawrence T Goodnough
Journal:  Transfusion       Date:  2012-03-13       Impact factor: 3.157

5.  Clearance of maternal isohemagglutinins from infant circulation (CME).

Authors:  Salima Shaikh; Steven R Sloan
Journal:  Transfusion       Date:  2010-10-26       Impact factor: 3.157

Review 6.  Problems associated with passively transfused blood group alloantibodies.

Authors:  G Garratty
Journal:  Am J Clin Pathol       Date:  1998-06       Impact factor: 2.493

7.  Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion.

Authors:  Chenell Donadee; Nicolaas J H Raat; Tamir Kanias; Jesús Tejero; Janet S Lee; Eric E Kelley; Xuejun Zhao; Chen Liu; Hannah Reynolds; Ivan Azarov; Sheila Frizzell; E Michael Meyer; Albert D Donnenberg; Lirong Qu; Darrel Triulzi; Daniel B Kim-Shapiro; Mark T Gladwin
Journal:  Circulation       Date:  2011-07-11       Impact factor: 29.690

8.  Fucosyltransferase 2 non-secretor and low secretor status predicts severe outcomes in premature infants.

Authors:  Ardythe L Morrow; Jareen Meinzen-Derr; Pengwei Huang; Kurt R Schibler; Tanya Cahill; Mehdi Keddache; Suhas G Kallapur; David S Newburg; Meredith Tabangin; Barbara B Warner; Xi Jiang
Journal:  J Pediatr       Date:  2011-01-22       Impact factor: 4.406

9.  Safety and efficacy of AS-1 red blood cell use in neonates.

Authors:  R Jain; C Jarosz
Journal:  Transfus Apher Sci       Date:  2001-04       Impact factor: 1.764

10.  Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease.

Authors:  Josep Figueras-Aloy; José M Rodríguez-Miguélez; Martin Iriondo-Sanz; María-Dolores Salvia-Roiges; Francesc Botet-Mussons; Xavier Carbonell-Estrany
Journal:  Pediatrics       Date:  2009-11-30       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.